Drug Price Trends for DIVALPROEX SOD DR

Average Pharmacy Cost for DIVALPROEX SOD DR

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DIVALPROEX SOD DR 125 MG TAB	00832-7122-15	0.05891	EACH	2024-12-18
DIVALPROEX SOD DR 125 MG TAB	29300-0138-05	0.05891	EACH	2024-12-18
DIVALPROEX SOD DR 125 MG TAB	57237-0106-01	0.05891	EACH	2024-12-18
DIVALPROEX SOD DR 125 MG TAB	29300-0138-01	0.05891	EACH	2024-12-18
DIVALPROEX SOD DR 500 MG TAB	69452-0435-30	0.16434	EACH	2024-12-18

DIVALPROEX SOD DR Market Analysis and Financial Projection

Market Analysis and Price Projections for Divalproex Sodium

Market Overview

The divalproex sodium market is poised for significant growth, driven by several key factors. This drug, commonly used to treat conditions such as bipolar disorder, epilepsy, and migraine headaches, has seen a steady increase in demand due to its therapeutic efficacy.

Market Size and Growth

The global divalproex sodium market was valued at USD 2,487.11 million in 2023 and is projected to reach USD 2,694.54 million in 2024. By 2032, the market is expected to grow to USD 5,114.4 million, reflecting a compound annual growth rate (CAGR) of 8.34% during the forecast period (2024-2032)[3].

Geographical Distribution

The North American market is currently the largest for divalproex sodium, driven by increasing demand for effective treatments for neurological and psychiatric disorders. However, the Asia-Pacific region is expected to be the fastest-growing market, fueled by rising healthcare access and increasing awareness of mental health issues[1][3].

Market Drivers

Several factors are driving the growth of the divalproex sodium market:

Growing Incidence Rates of Bipolar Disorders

The increasing prevalence of bipolar disorders worldwide is a significant driver. Bipolar disorder has a lifetime prevalence of about 1% and a one-year prevalence of about 0.5% globally. The COVID-19 pandemic has further increased the number of people suffering from anxiety and depressive illnesses, which has boosted the demand for divalproex sodium[1][4].

Expanding Patient Pool with Epilepsy and Migraine Headaches

The rising patient pool with epilepsy and migraine headaches is another key factor. These conditions are becoming more prevalent, and divalproex sodium is a preferred treatment option due to its effectiveness[1][4].

Increasing Government Initiatives and Research and Development

Government initiatives and advancements in research and development are also propelling market growth. These efforts are aimed at introducing new therapeutic products and improving existing formulations, making divalproex sodium more accessible and effective[1][4].

Market Restraints

Despite the growth drivers, the market faces several restraints:

Stringent Regulations

Regulatory bodies like the FDA have issued black box warnings highlighting the risks of hepatotoxicity, pancreatitis, and fetal harm associated with divalproex sodium use. These warnings can impact market growth[4].

Neurobehavioral Adverse Effects and Birth Defects

The drug is associated with neurobehavioral adverse effects, birth defects, and suicidal tendencies, which can deter some patients and healthcare providers from using it[4].

Price Projections and Cost Analysis

The cost of divalproex sodium varies based on the dosage and formulation:

Oral Delayed Release Capsules and Tablets

• For 30 capsules of 125 mg divalproex sodium, the cost can range from $33.01 to $48.69.
• For 100 tablets of 250 mg divalproex sodium, the cost can range from $29.81 to $55.32[2].

Extended Release Tablets

• For 30 tablets of 500 mg divalproex sodium, the cost is around $41.40.
• For larger quantities, the cost per unit decreases, but the total cost increases accordingly[2].

Cost-Effectiveness Analysis

A cost analysis comparing divalproex sodium extended-release (DVPX-ER) to valproic acid (VPA) in patients with bipolar disorder found that DVPX-ER results in lower total costs. The study indicated that the expected total cost per patient was $25,336.13 for DVPX-ER, compared to $34,208.84 for VPA, highlighting the cost-effectiveness of divalproex sodium extended-release[5].

Generic Versions and Personalized Medicine

The market is witnessing a trend towards generic versions of divalproex sodium, which has made the drug more affordable and accessible. Additionally, there is a growing focus on personalized medicine, with advancements in genomics and biotechnology enabling tailored treatments based on individual patient profiles. This trend is expected to drive better outcomes and improve the therapeutic effectiveness of divalproex sodium[3].

Investment Opportunities

The divalproex sodium market presents several investment opportunities, particularly in the development of new drug formulations and combination therapies. Emerging markets, such as Asia-Pacific, Latin America, and Africa, are expected to see a steady rise in demand for divalproex sodium, especially for generic versions, due to their cost-effectiveness[3].

Key Players

The divalproex sodium market is consolidated, with several major players dominating the market. These include AbbVie Inc., Zydus Cadila, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd, Lupin Pharmaceuticals Inc., Orchid Pharma Ltd, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Ltd, and Abbott Laboratories[1].

Impact of COVID-19

The COVID-19 pandemic has had a significant impact on the divalproex sodium market. Initially, it altered healthcare delivery methods, increasing the use of telemedicine. However, it also underscored the importance of mental health, potentially boosting demand for divalproex sodium as more people seek treatment for anxiety, depressive illnesses, and other mental health disorders[1][4].

Key Takeaways

• The divalproex sodium market is projected to grow significantly, driven by increasing prevalence of bipolar disorders, epilepsy, and migraine headaches.
• The market is expected to reach USD 5,114.4 million by 2032, with a CAGR of 8.34% during the forecast period.
• North America is the largest market, but the Asia-Pacific region is expected to be the fastest-growing.
• Generic versions and personalized medicine are key trends shaping the market.
• The drug faces restraints due to stringent regulations and adverse effects.

Frequently Asked Questions

1. What is the projected growth rate of the divalproex sodium market?

The divalproex sodium market is projected to register a CAGR of 8.34% during the forecast period (2024-2032)[3].

2. Which region is expected to be the fastest-growing market for divalproex sodium?

The Asia-Pacific region is expected to be the fastest-growing market for divalproex sodium[1][3].

3. What are the primary drivers of the divalproex sodium market?

The primary drivers include the growing incidence rates of bipolar disorders, expanding patient pool with epilepsy and migraine headaches, increasing government initiatives, and rising research and development activities[1][4].

4. How does the cost of divalproex sodium compare to valproic acid in treating bipolar disorder?

Divalproex sodium extended-release is found to result in lower total costs compared to valproic acid in treating bipolar disorder[5].

5. Which companies are major players in the divalproex sodium market?

Major players include AbbVie Inc., Zydus Cadila, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd, Lupin Pharmaceuticals Inc., Orchid Pharma Ltd, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Ltd, and Abbott Laboratories[1].

Cited Sources

1. Mordor Intelligence: Divalproex Sodium Market Size & Share Analysis.
2. Drugs.com: Divalproex sodium Prices, Coupons, Copay Cards & Patient Assistance Programs.
3. Global Growth Insights: Divalproex Sodium Market Size, Share - Forecast To 2032.
4. Mordor Intelligence: Global Divalproex Sodium Market Size | Mordor Intelligence.
5. PubMed: Cost analysis of divalproex sodium extended-release compared to valproic acid in patients with bipolar disorder.